{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/olecranon-bursitis/diagnosis/differential-diagnosis/","result":{"pageContext":{"chapter":{"id":"7ad7f12d-d8f0-59d8-8841-9ecbe656356c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":2,"htmlHeader":"<!-- begin field 6a55f158-c64e-41c6-967b-3c723c3fe4f7 --><h2>What else might it be?</h2><!-- end field 6a55f158-c64e-41c6-967b-3c723c3fe4f7 -->","summary":"","htmlStringContent":"<!-- begin item 70335253-7965-408e-972c-3924a7a8e0f3 --><!-- begin field f78575c0-853b-4ffb-a5f0-398309f74617 --><ul><li>The localized swelling of olecranon bursitis is usually distinctive, but conditions that may appear clinically similar include:<ul><li><strong>Rheumatoid arthritis </strong>— the whole joint is inflamed, rather than a localized, fluctuant swelling over the olecranon process. Nodules may cause swelling over the olecranon region, but they are firm with no fluctuance. Other joints may also be affected. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/rheumatoid-arthritis/\">Rheumatoid arthritis</a>.</li><li><strong>Septic arthritis </strong>— the joint is swollen (with absence of localized bursal swelling) and there is a limited, painful range of movement on joint examination. Secondary septic arthritis can also be a rare complication of olecranon bursitis.</li><li><strong>Gout or, rarely, pseudogout </strong>— joints (for example the first metatarsophalangeal joint in gout, or knee or wrist in pseudogout) may have been affected in the past, and laboratory examination of aspiration fluid will show crystals. Acute gout may occur in the bursa with or without local tophi. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gout/\">Gout</a>.</li><li><strong>Cellulitis </strong>— this may coexist with septic olecranon bursitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cellulitis-acute/\">Cellulitis - acute</a>.</li><li><strong>Tennis elbow (lateral epicondylitis)</strong> — tenderness to palpation over the origin of the extensor carpi radialis brevis tendon. For more information, please see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/tennis-elbow/\">Tennis elbow</a>.</li><li><strong>Trauma </strong>(such as a fracture, tendon or ligament injury) — the history is usually indicative of more significant trauma.</li><li><strong>Local bone or soft tissue tumours</strong> — these can be clinically similar to any local bursitis, with pain, swelling, and erythema. Findings suggestive of neoplasia, such as rapid expansion, overt invasive skin changes, and weight loss, should be observed with suspicion as recurrent sarcomas have been initially misdiagnosed as olecranon bursitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/bone-soft-tissue-sarcoma-recognition-referral/\">Bone and soft tissue sarcoma - recognition and referral</a>.</li></ul></li></ul><!-- end field f78575c0-853b-4ffb-a5f0-398309f74617 --><!-- end item 70335253-7965-408e-972c-3924a7a8e0f3 -->","topic":{"id":"677058a2-327c-5c74-b020-fa294dc001d6","topicId":"2b5681b1-a6ac-486f-9c29-562f1d00c942","topicName":"Olecranon bursitis","slug":"olecranon-bursitis","lastRevised":"Last revised in January 2021","chapters":[{"id":"a4276506-6266-5cf4-a65d-b517b5e29073","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5f6379bf-0c3e-5f36-b626-ae14f093855a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"30dc5fe8-8e10-5195-be9c-2032a2fe9c29","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"606247ee-02bd-5fbb-ac4e-00181cb9d573","slug":"changes","fullItemName":"Changes"},{"id":"13cfdc08-b4d8-56a4-a5ac-0dfa1d7e6cfe","slug":"update","fullItemName":"Update"}]},{"id":"3f962ec9-103d-50a6-876c-4a47fb7de1c6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c7da3eeb-0643-5b34-ab2c-8ba9d3db1032","slug":"goals","fullItemName":"Goals"},{"id":"ce4821e2-3cc9-5e64-a68c-2347bb4c8b71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d54ee925-bde2-5a23-a8d7-5890790b3298","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55611326-78d9-5af9-a3d8-3243f894aff6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"97a3cb4a-8ad1-5279-9a00-d3071c8afd3f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ae95433-ad22-5338-aab8-270312eb6fa0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9d59d92b-a3ce-5a17-ad08-8bdcd5032439","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"198864d0-53c2-5b2c-b236-08be4dd0177d","slug":"definition","fullItemName":"Definition"},{"id":"1c159260-37b3-563a-831f-16da306c92e0","slug":"causes","fullItemName":"Causes"},{"id":"83714e1b-4423-54d1-893d-80c2a92a842a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e2b0682f-f14b-5991-9d25-9d0a5572ae36","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a6ff79ed-b8bd-5dde-b777-048ebe2f83e8","slug":"complications","fullItemName":"Complications"}]},{"id":"f4ab30bf-b462-5a3f-bf5c-a27ae9d3e6ff","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1d3747f8-bed3-50aa-9617-789459b5adf6","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"7ad7f12d-d8f0-59d8-8841-9ecbe656356c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"653f7410-1fe1-5ae6-a30f-00e9b38f6285","slug":"aspiration","fullItemName":"Aspiration"}]},{"id":"33abb1c3-d06d-580c-8e89-c9f79202fcdd","fullItemName":"Management","slug":"management","subChapters":[{"id":"8eafa19f-9b61-5217-a60d-8b7150c8d22e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4cc6cfee-67bb-5942-a9b4-d95ff1d2b51a","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0c0460df-e8f1-55c6-9812-ab8d4105711c","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"fa9d8342-ae93-5e02-bc7e-bc3667cbfbc9","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cdb27da7-1335-559d-9d4b-3fc3a0b6bc9b","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"004b3dea-95a9-59e3-8f0e-2c801e5ebb1a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06e783b5-d47f-55ea-b7be-a3cbd73f4ddb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1fb7925d-db93-5872-9164-840da5cf1d91","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6a47a3d4-5551-565a-a0f6-618797e318a7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8a12dab5-123e-505b-bb29-69626a4ef54e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3600086-ecd1-5ccd-9711-0f1444616612","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87436259-d98d-5e39-ba2d-28c6133751e5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5c35d7b1-2c5b-5fd5-9de1-d0a85c2d7931","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f4ab30bf-b462-5a3f-bf5c-a27ae9d3e6ff","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"f9107167-0f39-588e-a080-29d8aab61237","slug":"basis-for-recommendation-40b","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field b79af734-f1b6-43f5-8eb3-56fd332e40ae --><h3>Basis for recommendation</h3><!-- end field b79af734-f1b6-43f5-8eb3-56fd332e40ae -->","summary":null,"htmlStringContent":"<!-- begin item 40bbd3b7-8da0-45cc-acd8-8e1200292b90 --><!-- begin field 2005d5b5-17be-48e8-ab63-4a09f7314032 --><h4>Differential diagnosis</h4><ul><li>The information on differential diagnoses is based on expert opinion in review articles on the diagnosis and management of olecranon bursitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Wasserman et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Aaron et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Smith, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Blackwell et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Reilly and Kamineni, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BMJ Best Practice, 2016</a>] and from previous expert reviewers of this CKS topic.</li></ul><!-- end field 2005d5b5-17be-48e8-ab63-4a09f7314032 --><!-- end item 40bbd3b7-8da0-45cc-acd8-8e1200292b90 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}